東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Design and mechanism study of anti-c...

Stevens Institute of Technology.

FindBook

Google Book

Amazon

博客來

Design and mechanism study of anti-cancer lytic peptides.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Design and mechanism study of anti-cancer lytic peptides./
作者:	Tu, Zhigang.
面頁冊數:	231 p.
附註:	Adviser: Junfeng Liang.
Contained By:	Dissertation Abstracts International70-03B.
標題:	Biology, Cell. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3351566
ISBN:	9781109078718

Design and mechanism study of anti-cancer lytic peptides.
Tu, Zhigang.

Design and mechanism study of anti-cancer lytic peptides. - 231 p.

Adviser: Junfeng Liang.

Thesis (Ph.D.)--Stevens Institute of Technology, 2009.

Multi-drug resistance (MDR) is one of the major problems of today's disease control and therapies, especially for the treatment of cancers. Lytic peptides, an abundant group of natural or artificial molecules killing cells through membrane disruption, can overcome MDR. But anti-cancer lytic peptides also have a fatal defect: deficiency of the selectivity between targets and normal tissues. My thesis focuses on constructing lytic peptides with tumor-selective killing ability.

ISBN: 9781109078718Subjects--Topical Terms:

1017686
Biology, Cell.

Design and mechanism study of anti-cancer lytic peptides.
LDR:02153nam 2200301 a 45 001 862471
005 20100720
008 100720s2009 ||||||||||||||||| ||eng d
020 $a 9781109078718
035 $a (UMI)AAI3351566
035 $a AAI3351566
040 $a UMI $c UMI
100 1 $a Tu, Zhigang. $3 1030289
245 1 0 $a Design and mechanism study of anti-cancer lytic peptides.
300 $a 231 p.
500 $a Adviser: Junfeng Liang.
500 $a Source: Dissertation Abstracts International, Volume: 70-03, Section: B, page: 1541.
502 $a Thesis (Ph.D.)--Stevens Institute of Technology, 2009.
520 $a Multi-drug resistance (MDR) is one of the major problems of today's disease control and therapies, especially for the treatment of cancers. Lytic peptides, an abundant group of natural or artificial molecules killing cells through membrane disruption, can overcome MDR. But anti-cancer lytic peptides also have a fatal defect: deficiency of the selectivity between targets and normal tissues. My thesis focuses on constructing lytic peptides with tumor-selective killing ability.
520 $a Different strategies have been tried and applied. The first and the most effective approach, is to replace lysine or arginine residues by histidine ones. By this way, we have designed three series of lytic peptides based on three peptide templates. The second approach is to formulate ion-peptide complexes to control the activities of lytic peptides. The third approach is to produce pro-drug type of lytic peptides which can be activated by the specific enzymes over-expressed on surfaces of tumor cells. The fourth approach is to design lytic peptides with self-assembly feature. Positive and promising results have been obtained from both in vitro and in vivo studies. In addition, detailed acting mechanisms of the different lytic peptides have also been studied.
590 $a School code: 0733.
650 4 $a Biology, Cell. $3 1017686
650 4 $a Biophysics, Medical. $3 1017681
650 4 $a Health Sciences, Pharmacology. $3 1017717
690 $a 0379
690 $a 0419
690 $a 0760
710 2 $a Stevens Institute of Technology. $3 1019501
773 0 $t Dissertation Abstracts International $g 70-03B.
790 $a 0733
790 1 0 $a Liang, Junfeng, $e advisor
791 $a Ph.D.
792 $a 2009
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3351566